AETHLON MEDIC.NEW DL-001
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, … Read more
AETHLON MEDIC.NEW DL-001 (EJU) - Total Liabilities
Latest total liabilities as of December 2025: €1.34 Million EUR
Based on the latest financial reports, AETHLON MEDIC.NEW DL-001 (EJU) has total liabilities worth €1.34 Million EUR as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AETHLON MEDIC.NEW DL-001 - Total Liabilities Trend (2020–2025)
This chart illustrates how AETHLON MEDIC.NEW DL-001's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
AETHLON MEDIC.NEW DL-001 Competitors by Total Liabilities
The table below lists competitors of AETHLON MEDIC.NEW DL-001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MONDELEZ INT-A - Dusseldorf Stock Exchang
DU:KTF
|
Germany | €44.30 Billion |
|
BENCHMARK ELECTRS
MU:BMU
|
Germany | €1.05 Billion |
|
Megaron SA
WAR:MEG
|
Poland | zł10.61 Million |
|
OCCID.PETROL CORP
MU:OPC
|
Germany | €50.87 Billion |
|
Binah Capital Group, Inc. Warrants
NASDAQ:BCGWW
|
USA | $49.47 Million |
|
First Colombia Gold Corp
PINK:FCGD
|
USA | $162.38K |
|
International Stem Cell Corp
OTCQB:ISCO
|
USA | $9.06 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down AETHLON MEDIC.NEW DL-001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AETHLON MEDIC.NEW DL-001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AETHLON MEDIC.NEW DL-001 (2020–2025)
The table below shows the annual total liabilities of AETHLON MEDIC.NEW DL-001 from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €2.24 Million | -9.83% |
| 2024-03-31 | €2.48 Million | +1.43% |
| 2023-03-31 | €2.44 Million | +0.75% |
| 2022-03-31 | €2.43 Million | +76.45% |
| 2021-03-31 | €1.38 Million | +23.87% |
| 2020-03-31 | €1.11 Million | -- |